Figure 3.

Proteasome-enriched domains disappear in the presence of proteasome inhibitors. HeLa cells were either mock treated (A) or incubated for 3 h in the presence of E64 (B), lactacystin (C), and MG132 (D). The cells depicted in E were allowed to recover for 12 h after treatment with MG132. All cells were immunolabeled with antibodies directed against the 20S catalytic core of the proteasome. Bar, 10 μm. (F) Proportion of cells containing proteasome-enriched domains and the number of bodies per cell were estimated. After treatment with E64, the proportion of cells that contain bodies does not significantly differ from the control population. The graph depicts means ± SEs (three separate experiments were performed and a total of 300 cells analyzed for each drug treatment).